BOEHRINGER-INGELHEIM
9.5.2023 14:36:33 CEST | Business Wire | Press release
Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 study (NCT05658107) to assess the safety, tolerability, and pharmacokinetics in healthy volunteers. Boehringer Ingelheim is already a global leader in the treatment of pulmonary fibrosis, and the initiation of clinical development of the anti-IL-11 treatment reflects the company’s long-term commitment to combat fibrotic disease across therapeutic areas. The IL-11 inhibitor antibody is the first of its kind to reach clinical development stage and is based on a partnership between the Company and Enleofen Bio Pte. Ltd. (Enleofen), with a goal to improve patient outcomes.
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis, or scarring, of various organs and tissues. It can be triggered by different factors (such as infections, inflammation, autoimmune disorders, degenerative diseases, tumors, and injury), can cause organ dysfunction/failure, and affect the quality of life and survival of patients. Some examples of fibrotic diseases are, systemic sclerosis, graft-versus-host disease as well as heart, lung, liver, and kidney fibrosis. Current treatments have led to progress in some areas, however fibrotic diseases remain to be a leading cause of morbidity/mortality and account for more than one third of deaths worldwide.
IL-11 plays a key role in fibrosis across multiple organs and pre-clinical studies have shown that anti-IL-11 treatment has the potential to stop – and even reverse fibrosis – in different fibrotic diseases. Boehringer Ingelheim joined forces with Enleofen, a leader in IL-11 biology, in 2020.
“The initiation of this trial is an important milestone for Boehringer Ingelheim and brings us closer to achieving our aim of transforming lives of people living with fibrotic diseases,” said Clive R. Wood, Ph.D., Corporate Senior Vice President and Global Head of Discovery Research at Boehringer Ingelheim. “The effects shown for anti-IL-11 preclinically are impressive and could, if confirmed in the clinic, herald a dramatic advance in the treatment of fibrotic diseases.”
“Enleofen is very excited to see the IL-11 inhibitor partnership with Boehringer Ingelheim, a leader in anti-fibrotic therapy R&D, moving forward into the clinic to address unmet patient needs,” said Prof Stuart Cook, co-founder of Enleofen and Tanoto Foundation Professor of Cardiovascular Medicine at the SingHealth Duke-NUS Academic Medical Centre and the Cardiovascular & Metabolic Disorders Programme at Duke-NUS Medical School, Singapore.
The IL-11 program complements Boehringer Ingelheim’s clinical fibrotic disease pipeline portfolio which includes BI 1015550, a phosphodiesterase 4B (PDE4B) inhibitor, under investigation in two Phase III randomized, double-blind, placebo-controlled trials—FIBRONEER™-IPF (NCT05321069) and FIBRONEER™-ILD (NCT05321082)—to investigate the efficacy, safety and tolerability of BI 1015550 over at least 52 weeks in patients with IPF and in patients with other progressive fibrosing ILDs and several other clinical stage programs.
###
About Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com
About Enleofen
Enleofen is a Singapore-based biotech company developing first-in-class antibody therapeutics for the treatment of fibro-inflammatory human diseases. The initial discovery science and drug target validation was carried out by founders Stuart Cook and Sebastian Schäfer at the National Heart Centre Singapore at SingHealth and Duke-NUS Medical School and was subsequently licensed to Enleofen. Since 2017, the company has invested extensively in target validation, drug development, and preclinical studies, with the support of experienced international life sciences executives and investors, including founding directors Jeffrey Lu and Andrew Khoo.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005762/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Amazfit Introduces T-Rex Dual Solar, the First AMOLED Smartwatch with Dual-Sided Solar Charging22.9.2026 13:00:00 CEST | Press release
Built for adventures beyond the grid, T-Rex Dual Solar combines a bright AMOLED display with dual-sided solar energy recovery designed to extend battery life when access to traditional power is limited. Amazfit, a leading global smart wearable brand owned by Zepp Health, today announced the T-Rex Dual Solar, a premium expedition smartwatch built for long-distance and multi-day exploration. Launching on the autumnal equinox — a day defined by the balance of sunlight and darkness — the T-Rex Dual Solar is the world’s first AMOLED smartwatch featuring a dual-sided solar charging system, combining solar collection either through the display or through an innovative glass ceramic back plate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922588618/en/ The Amazfit T-Rex Dual Solar is the world’s first AMOLED smartwatch featuring a dual-sided solar charging system, combining solar collection either through the display or through
Saildrone USVs Receive Danish Flag Registration for European Operations22.9.2026 12:45:00 CEST | Press release
Saildrone today announced that the first four Saildrone Voyager USVs (unmanned surface vehicles) have been registered in Denmark and will operate under the Danish flag, marking the first time Saildrone USVs will operate under a national flag. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922488140/en/ A Saildrone Voyager operates in the Baltic Sea in support of maritime domain awareness missions. The 10-meter USV is one of the first Saildrone platforms registered in Denmark to operate under the Danish flag. The registration establishes a clear flag-state framework for Saildrone USVs operating internationally. Working together, Saildrone and the Danish Maritime Authority developed the regulatory framework necessary to register and operate unmanned surface vehicles under the Danish flag. “We are pleased that Saildrone has chosen Denmark as the flag state for the company’s uncrewed vessels. This underscores that Denmark, as
NIQ Announces Friendly Bid to Acquire The U Group & Co Limited, Expanding Trusted Intelligence for the AI Era22.9.2026 12:45:00 CEST | Press release
NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced that its wholly-owned Australian subsidiary, Nielsen Connect Australia Pty Ltd (NIQ Australia) has launched a conditional off-market offer for all outstanding shares of The U Group & Co Limited (The U Group) as a friendly takeover bid (Offer). The U Group is an Australian-based company specializing in first-party, consumer-consented purchase data collection through its ReceiptJar app, receipt intelligence, and AI-powered data processing capabilities. In connection with the Offer, NIQ Australia has lodged its Bidder's Statement with the Australian Securities and Investments Commission and dispatched the Offer materials to shareholders of The U Group in accordance with applicable Australian regulatory requirements. The Board of The U Group has unanimously recommended that shareholders accept the Offer for the reasons set out in the Target's Statement. The Offer reflects NIQ's commitment to strengthening trust
OKX Sets a New Standard for Account Protection with OKX Shield22.9.2026 12:30:00 CEST | Press release
Up to €500,000 in account protection for customers in EuropeOKX Shield builds on industry-leading safeguards and advanced account security OKX, a leading global cryptocurrency exchange and onchain technology company with more than 150 million customers worldwide, today launched OKX Shield. OKX Shield is an integrated security product suite combining sophisticated safeguards, visible protection status and the potential for customers to be paid back up to €500,000 following a third-party account-takeover. Account takeover fraud is a challenge for all financial businesses to protect customers against, with billions lost every year in Europe. The most recent EBA and ECB data shows €4.2 billion in payment fraud across Europe in 2024, which was up from €3.5 billion in 2023. Customers are being targeted directly, with attempts to compromise their accounts across financial platforms. OKX Shield brings together account-security enhancements with a new protection program, providing up to €500,00
Infobip Predicts 7.3 Billion Black Friday and Cyber Monday Interactions as AI Reshapes the 2026 Shopping Season22.9.2026 12:26:00 CEST | Press release
New research across nine markets finds 63% of consumers have used AI when shopping, while only 19% plan to wait until Black Friday week to begin their holiday shopping Global AI-first cloud communications platform Infobip predicts more than 7.3 billion customer interactions across Black Friday and Cyber Monday 2026, as AI and conversational channels transform how consumers discover products, receive offers and access support. New Infobip research also reveals that 63.2% of consumers have used an AI assistant or chatbot while shopping during the past 12 months. Black Friday is no longer a single shopping event. Infobip’s research shows that the shopping season now begins weeks earlier and continues through the entire customer journey. Nearly six in ten respondents will have started holiday shopping by early November, while only 19% wait until Black Friday week itself. This extended shopping window is creating new pressure for retailers to engage customers earlier, with better timing, mo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom